| |
Vital signs
|
Group Eb
|
Group Cc
|
P
|
|---|
|
T0
|
SBP
|
121.63 ± 16.26
|
122.64 ± 16.01
|
0.513
|
| |
DBP
|
74.92 ± 9.48
|
74.63 ± 8.80
|
0.738
|
| |
Respiratory rate
|
17.09 ± 1.81
|
17.04 ± 2.18
|
0.808
|
| |
Heart rate
|
74.45 ± 8.43
|
74.48 ± 9.75
|
0.978
|
|
T1
|
SBP
|
128.96 ± 17.74**
|
130.18 ± 17.05**
|
0.465
|
| |
DBP
|
79.04 ± 11.32**
|
78.85 ± 11.45**
|
0.864
|
| |
Respiratory rate
|
16.52 ± 2.40
|
16.89 ± 2.56
|
0.121
|
| |
Heart rate
|
78.69 ± 16.33
|
78.89 ± 14.97
|
0.893
|
|
T2
|
SBP
|
123.87 ± 16.07*
|
126.10 ± 16.68*
|
0.157
|
| |
DBP
|
76.20 ± 9.88*
|
77.12 ± 12.16*
|
0.390
|
| |
Respiratory rate
|
16.74 ± 2.19
|
17.12 ± 2.46
|
0.092
|
| |
Heart rate
|
76.82 ± 13.95*
|
76.54 ± 12.06*
|
0.822
|
|
T3
|
SBP
|
118.37 ± 15.23*
|
121.18 ± 15.53*
|
0.065
|
| |
DBP
|
72.82 ± 9.19*
|
74.00 ± 9.70*
|
0.209
|
| |
Respiratory rate
|
16.53 ± 1.85
|
16.72 ± 2.13
|
0.321
|
| |
Heart rate
|
74.06 ± 10.82*
|
74.59 ± 9.58*
|
0.598
|
|
T4
|
SBP
|
116.72 ± 15.43*
|
118.82 ± 15.19*
|
0.169
|
| |
DBP
|
71.27 ± 9.36*
|
72.07 ± 9.73*
|
0.399
|
| |
Respiratory rate
|
16.44 ± 1.78
|
16.62 ± 2.20
|
0.366
|
| |
Heart rate
|
72.81 ± 9.44*
|
73.62 ± 8.99*
|
0.378
|
|
T5
|
SBP
|
116.53 ± 14.86*
|
117.11 ± 14.46*
|
0.691
|
| |
DBP
|
70.64 ± 9.39*
|
70.63 ± 9.45*
|
0.986
|
| |
Respiratory rate
|
16.46 ± 1.84
|
16.54 ± 2.07
|
0.682
|
| |
Heart rate
|
72.65 ± 9.35*
|
72.76 ± 9.22*
|
0.905
|
- aT0: at admission, T1: before administration, T2: after administration at 30 min, T3: after administration at 2 h, T4: after administration at 4 h, T5: after administration at 6 h
- bGroup E (n = 209) was treated with nalbuphine hydrochloride diluted with saline to 1 mg/L.
- cGroup C (n = 228) was administered tramadol hydrochloride diluted with saline to 10 mg/L.
- *Difference is statistically significant compared with T1; **difference is statistically significant compared with T0
